Abstract  Introduction: Peptic ulcer treatment has for many years been Concentrated on reduction of intraluminal acidity. The efficacy of antacid agents in the treatment of gastric ulcer is, however, uncertain. Oxethazine, an H2-receptor antagonist with high acid reducing capacity, has been demonstrated in a few controlled studies to have a statistically better healing efficacy in gastric ulcer than placebo. The development of agents acting on the gastric mucosal barrier level, and having cytoprotective properties has provided a new method of combating peptic ulcer disease. Sucralfate, a basic aluminum salt of sucrose octasulphate, is one of the new cytoprotective agents and has in previous studies given healing rates comparable with those given by ranitidine in the treatment of both duodenal and gastric ulcer. Aims and Objective: The main purpose of this study the healing rates and symptom relief in patients with acute peptic ulcer treated with Sucralfate and Oxethazine Containing Antacids. Methodology: This was case series of 50 known cases of Peptic Ulcer disease 25 using Sucralfate (Group A) for treatment and 25 Oxethazine Containing Antacids for the (Group B) treatment. All the patients who have given informed written consent were included into study except patients having hypophosphatemia severe renal defect, Pregnancy, Any severe illness. Graph Pad Prism software was used to calculate statistical significance. Result: That the main risk factors were Mean age54±10.11 and 55.5±9.6, female sex 12/13 and 11/14, Smoker 42% and 43%, NSAIDS 24% and 23%, Alcohol 64%, 67%, Coffee 80%, 88% were present in both the Group i.e. Sucralfate (Group A) and Oxethazine Group (Group B) and the risk factors were equally distributed in both the groups as (p.0.05,ns).At the beginning of the treatment in Group A and Group B was14.1±6.1mm and 13±5.5mm respectively so there was not statistical difference in between them (p>0.05,t=0.89,df=48,ns). At 8 weeks also the size were 8.8±4.4mm and 11±5.4mm mm and there was not statistical difference in between them (P>0.05,t=1.85,df=48,ns). 12 weeks the mean size was 4.1±1.2mm and 9.5±5.4mm there was significant statistical difference in between them (P<0.001, t=6.5, df=48,hs). 16 weeks the mean 2.2±.82mm and 7.5± 3.4mm, highly significant statistical difference (*P<0.005,t=5.5,df=48,hs) respectively in Group A and Group B. Conclusion: Sucralfate has excellent role in the ulcer healing over the Oxethazine group so; it should be used in the treatment of peptic ulcer where ever it is possible.

Key Words: Sucralfate, Oxethazine, NSAIDs